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Abstract
The development of resistance mutations in drug-targeted HIV-1 genes compromises the success of anti-
retroviral therapy (ART) programs. Genotyping of these mutations enables adjusted therapeutic decisions both
at the individual and population level. We investigated over time the prevalence of HIV-1 primary drug
resistance mutations in treatment-naive patients and described the HIV-1 subtype distribution in a cohort in
rural Tanzania at the beginning of the ART rollout in 2005–2007 and later in 2009. Viral RNA was analyzed in
387 baseline plasma samples from treatment-naive patients over a period of 5 years. The reverse transcriptase
(RT) and protease genes were reversely transcribed, polymerase chain reaction (PCR) amplified, and directly
sequenced to identify HIV-1 subtypes and single nucleotide polymorphisms associated with drug resistance
(DR-SNPs). The prevalence of major DR-SNPs in 2005–2007 in the RT gene was determined: K103N (5.0%),
Y181C (2.5%), M184V (2.5%), and G190A (1.7%), and M41L, K65KR, K70KR, and L74LV (0.8%). In samples from
2009 only K103N (3.3%), M184V, and T215FY (0.8%) were detected. Initial frequencies of subtypes C, A, D, and
recombinants were 43%, 32%, 18%, and 7%, respectively. Later similar frequencies were found except for the
recombinants, which were found twice as often (15%), highlighting the subtype diversity and a relatively stable
subtype frequency in the area. DR-SNPs were found at initiation of the cohort despite very low previous ART
use in the area. Statistically, frequencies of major mutations did not change significantly over the studied 5-year
interval. These mutations could reflect primary resistances and may indicate a possible risk for treatment failure.
Introduction
It is universally recognized that combined anti-retroviral therapy (ART) has dramatically reduced HIV-
related mortality worldwide.1,2 However, one major concern
is that a rapid and not appropriately controlled scaling up
of ART may accelerate the selection of drug resistance-
associated mutations and transmission of HIV drug-resistant
strains in a given population. This could impair basic ART
programs as well as strategies for reducing HIV morbidity and
mortality.3
The genetic diversity among HIV-1 subtypes is extensive.
Based on data from the Los Alamos database the median
percentage of amino acid differences within a given subtype
was found to be 17% in Env and 8% in Gag, whereas inter-
subtype differences were 25% and 17%, respectively.4 In
contrast to the highly variable Env, the pol sequence is more
conserved.4,5 Different HIV-1 subtypes exhibit differences in
frequency and route of virus transmission, in the pathogenesis
of the disease as well as in the kinetics and mechanisms of
drug resistance development, thus potentially affecting HIV-1
disease management.3,6,7 In view of the above, we aimed to
investigate key resistance mutations in the reverse transcrip-
tase (RT) and protease genes following ART rollout in a rural
setting in Ifakara, Tanzania.
In Tanzania, the first cases of HIV-1 infection were ob-
served and reported in the Kagera region in 1983,8 and by
2009 HIV prevalence in adults between 15 and 49 years of age
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was estimated to be 5.7% (6.6% women, 4.6% men), corre-
sponding to 1.5 million infected people. The National ART
program in Tanzania started in 2004.9 The default first line
drugs in Tanzania were zidovudine/stavudine, lamivudine,
and nevirapine/efavirenz, and the second line drugs were
abacavir, didanosine, and lopinavir/ritonavir or indinavir/
ritonavir. By 2009 more than 454,000 Tanzanian HIV-1 pa-
tients were in need of ART (according to the 2002 WHO cri-
teria for the initiation of ART) whereas only about 235,000
patients received ART.10 However, according to the more
recent WHO criteria for initiation of ART published in 201011
only one-third of the eligible patients in Tanzania were actu-
ally on ART. With many stakeholders supporting ART in the
country, the Ministry of Health and Social Welfare (MoHSW)
of Tanzania currently works on further expanding ART cov-
erage through its National Aids Control Programme (NACP).
Studies on the transmission of primary HIV-1 drug resis-
tance in Tanzania are few and limited to urban areas with
large HIV-1 sentinel centers, e.g., Mbeya, Kagera, Kili-
manjaro, and Dar es Salaam.12,13 Corresponding data about
the situation in rural areas are needed, as 80% of Tanzanians
live outside the urban centers, and these surveillance data will
add to a more precise and reliable picture of the HIV drug
resistance situation in Tanzania.
In late 2004 an HIV cohort was established in Morogoro,
rural Tanzania. The aim of this Kilombero-Ulanga-Anti-
retroviral-Cohort (KIULARCO) was to implement the care
and treatment of HIV/AIDS patients according to Tanzania
NACP guidelines, to strengthen infrastructure, to provide
education of staff, to conduct research on optimal strategies
for delivering treatment, and to conduct follow-up care in a
resource-limited and rural setting in Tanzania.4,14
To date, a total of 5,748 HIV-infected individuals have been
enrolled at the Chronic Disease Center of Ifakara (CDCI).
After a patient is enrolled, biomedical data are collected lon-
gitudinally. Blood samples are routinely collected at enroll-
ment, before initiation of ART, and at different time points
during visits to the clinic. Clinical and immunological pa-
rameters of patients under ART are assessed routinely during
follow-up visits. Details on the population and structure of the
KIULARCO cohort have been described previously.14,15
This study aimed to investigate the prevalence of HIV-1
drug resistance mutations in treatment-naive patients and to
establish HIV-1 subtypes in the KIULARCO cohort in Ifakara
Tanzania between 2005–2007 and 2009.
Materials and Methods
Ethical considerations
The KIULARCO study was approved by ethics review
bodies of Tanzania, the Ifakara Health Institute (IHI) Institu-
tional Review Board, the National Institute for Medical Re-
search (NIMR), and the Ethics Committee of the University
and State of Basel (EKBB). Patients were asked for their con-
sent before participation in this study.
Study site and subjects
Patients were enrolled at the CDCI, which serves as a Care
and Treatment Center for HIV/AIDS patients and is affiliated
with the Ifakara Health Institute (IHI) and St. Francis Referral
Hospital (SFRH). The SFRH is an important health facility in the
Kilombero and Ulanga districts in Morogoro, southeast Tan-
zania, and serves a population of about 600,000 individuals. It is
estimated that more than 30,000 individuals infected with
HIV-1 live in the area.14 By July 2008, a total of 2,394 patients
had been enrolled in the CDCI.14,15 As of October 2011, the
cumulative number of patients enrolled in CDCI was 5,748, of
which 3,664 (63.7%) were females and 2,084 (36.3%) were males.
Depending on their CD4 counts and HIV-1 WHO clinical
staging, participants either received ART (CD4 cell counts
£ 200 cells/ll regardless of WHO stage, CD4 counts £ 350
cells/ll and WHO clinical stage 3, or WHO stage 4 regardless
of CD4 cell count) or continued to be regularly followed up
every 3 months. Before ART initiation, patient blood was
drawn and plasma prepared and stored at - 80C. Data on
clinical, virological, and immunological parameters, and de-
mographic data of the patients (i.e., CD4 count, full blood
picture, viral load, WHO clinical staging at enrollment, age,
sex, and home town or village) were collected.
A total of 187 plasma samples from the time period 2005–
2007 were randomly selected from all baseline samples col-
lected prior to initiation of ART. Of those samples, 137 were
derived from patients starting ART immediately after this test
sample was collected. Fifty samples were chosen from HIV-1-
infected patients, who were not yet eligible for initiation of
ART. A second survey was conducted in 200 patients enrolled
in the cohort in 2009. The 2009 inclusion criteria were HIV-1-
positive patients, age > 18 years, and recent CD4 counts > 250
cells/ll (WHO clinical stage 1 or 2) or > 350 cells/ll (WHO
clinical stage 3). All plasma aliquots were sent to Basel,
Switzerland, for molecular genotyping.
RNA extraction, RT-PCR, PCR, and sequencing
Viral RNA was extracted from plasma with either the
QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) or
the Macherey-Nagel NucleoSpin RNA Virus Kit (Macherey-
Nagel GmbH & Co KG, Neumann-Neander, Germany) using
the manufacturer’s protocol.
RT was performed using specific primer RT2 (5¢-GA
TAAGCTTGGGCCTTATCTATTCCAT-3¢), AffinityScript RT
Buffer (500 mM Tris-HCl, pH 8.3, 750 mM KCl, 30 mM
MgCl2), 2ll of 100 mM DTT (Stratagene, La Jolla, CA), 0.8 ll
dNTP mix (25 mM each dNTP), 1 ll of an RNase inhibitor,
RNase Out (40 U/ ll), 1ll AffinityScript Multiple Tempera-
ture Reverse Transcriptase, 1 ll specific Primer RT2 (10 lM),
HPLC purified, and 9.5 ll RNA sample. RT was performed
with the following thermal conditions: 42C for 35 min, 55C
for 25 min, 70C for 15 min, and 5C for 15 min.
Primary polymerase chain reaction (pPCR) was done using
Advantage cDNA Polymerase according to the supplier’s
protocol (Clontech Laboratories Inc., Mountain View, CA) with
some modifications. Reverse and forward primers RT2 and
D1818 (5¢-AGAAGAAATGATGACAGCATGTCAGGGAGT-3¢)
were used. The pPCR mix contained 5ll 10 ·Advantage
buffer (Clontech), 10ll dNTP mix (2 mM), 2 ll reverse primer
RT2 (10lM), 2ll forward primer D1818 (10lM), 1ll Ad-
vantage Polymerase (5 U/ll), and 4ll of cDNA. The reaction
profile was 94C for 2 min, 94C for 20 s, 47C for 20 s, and 68C
for 2 min; 30 cycles and a final elongation step at 68C for
5 min were performed.
The nested PCR (nPCR) mix for amplification of the HIV-1
reverse transcriptase gene was 5ll 10·Pfu buffer (Promega
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Corporation, Madison, WI), 10 ll dNTP mix (2 mM), 2ll for-
ward primer JG103 5¢-AACAATggCCATTgACAgAA[I-Q]-3¢
(10 lM), 2ll reverse primer JG202 5¢-TCAggATggAgTTCA-
TAICCCA-3¢ (10lM), 0.7 ll FIREPol Polymerase (3 U/ll),
0.1 ll Pfu Polymerase (3 U/ll), and 2 ll pPCR product. The
thermocycling conditions were 94C for 2 min, followed by 30
cycles of 94C for 15 s, 47C for 15 s, 72C for 2 min, and a final
elongation step of 72C for 5 min. PCR conditions for ampli-
fication of the protease gene were the same as for the RT gene
except that a different primer set was used: forward primer
D2213A2 (5¢-AGCAGGATCCGAAAGACAGGGA-3¢) (10lM)
and reverse primer R2598L (5¢-CCATCCCGGGCTTTAATTT
TACTGG-3¢) (10lM). The nPCR products were purified with
the NucleoSpin Extract II kit (Macherey-Nagel) according to
the manufacturer’s protocol.
Direct sequencing of purified nPCR products was per-
formed either in house or by the commercial supplier Mac-
rogen, South Korea. The in-house protocol used either one of
the forward primers JG103 or PMF (5¢-AACTCAAGACTTT
TGGGAAGT-3¢) or one of the reverse primers JG202 or PMR
(5¢-TTGTCATGCTACTCTGGAATA-3¢). PMF and PMR are
centrally located sequencing primers for the RT gene. For
nested PCR amplification and sequencing of the protease
gene, the reagents and protocol used were the same as above
with the exception that forward primer D2213A2 and reverse
primer R2598L were used instead of RT-specific nested
primers. The sequences obtained for each sample were
aligned using the Seqscape Software Programme Version 2.6
(AB, Applied Biosystems, Foster City, CA). The consensus
sequences were assessed for drug resistance mutations by
using the Stanford University HIV Drug Resistance Database
HIVdb program Version 6.2.0.
HIV-1 subtyping
HIV-1 subtype information was obtained after submitting
the sequences to the Los Alamos subtyping tool and by con-
structing phylogenetic trees using the maximum likelihood
method based on the Tamura–Nei model. A total of nine
HIV-1 reference subtypes and one simian deficiency virus
were included in the phylogenetic analysis: subtype A1
(U51190, DQ676872, AF004885), subtype B (K03455), subtype
C (U46016, U52953), subtype D (U88822, M27323, K03454),
and simian immunodeficiency virus (U42720).
Viral load determination
Viral load was determined with a One Step Real-Time PCR
System (Applied Biosystems) by using a modification of the
manufacturer‘s instructions. cDNA was synthesized as
shown above, but using random primers (0.1 lg/ll). The
cDNA was then quantified by qRT-PCR. The qRT-PCR reac-
tion contained 12.5 ll TaqMan Gene Expression Master Mix,
0.125 ll forward primer M2227F, 5¢-AGC CTC AAT AAA
GCT TGC CTT G-3¢ (10 lM), 0.125ll reverse primer M2228R,
5¢-CGG GCG CCA CTG CTA G-3¢ (10lM), 0.5 ll of probe
HIV-FAM/BHQ with FAM as a reporter dye located at the 5¢
end and a black hole quencher at the 3¢ end, 5¢-TGC CCG TCT
GTT GTG TGA CTC TGG TAA-3¢ (10 lM), 5ll cDNA, and
RNase free water to a final 25ll reaction volume. qRT-PCR
thermocycling conditions were as follows: incubation (50C,
2 min), initial denaturation (95C, 10 min), and 44 cycles of
denaturation (95C, 30 s) and annealing and extension (60C,
1 min). Quantitation of cDNA was done relative to triplicate
standard curves generated in each run from serial dilutions of
a plasmid containing a viral DNA insert. Three ‘‘no template’’
controls were included for each run.
CD4+ T cell counts
A single platform technique (SPT) was used to enumerate
CD4 + T-helper cells using BD TruCount tubes (BD Bios-
ciences, San Jose, CA). Of EDTA whole blood 50ll was
stained using 5 ll monoclonal antibody mixture BD TriTEST
CD3-FITC/CD4-PE/CD8-PerCP (BD Biosciences) followed
by 450ll 1·BD lysis and fixative solution. Data acquisition
and analysis by the MultiTEST software were performed
using a three-color BD FACS Calibur (Becton Dickinson Im-
munocytometry Systems 2350).
Data analysis
Prevalence values were calculated as the proportion of
positives per all tested subjects. Differences between means
were calculated using the Student’s t test. All analyses were
done using Stata version 10 (StataCorp LP).
Results
Baseline characteristics
Our descriptive study was conducted in treatment-naive
patients recruited during two time periods: in 2005–2007, re-
presenting the first years of operation of the KIULARCO co-
hort, and in 2009, 4 years after the initial sampling period. The
clinical and demographic characteristics of the 120 patients
from 2005–2007 and of 119 patients from 2009 are summa-
rized in Tables 1 and 2. We failed to amplify PCR products
from 36% and 40% of samples of periods 2005–2007 and 2009,
respectively. Lack of amplification in such a high proportion
of samples was probably due to poor long-term storage of the
samples in Tanzania, likely resulting in degradation of viral
RNA. The median age of the study participants was 35 years in
2005–2007 and 40 years in 2009. The percentage of female study
participants was 68.4 in 2005–2007 and 62.3 in 2009. In baseline
samples from 2005–2007 the median CD4 cell count was 222
cells/ll and the median viral load was 50,805 copies/ml,
whereas in 2009 the median CD4 cell count was 420 cells/ll
and the median viral load was 39,920 copies/ml.
During the first years of our HIV cohort several parameters
were added or modified after incorporating improvements in
patient diagnosis or due to new technical capabilities in the
laboratory. Associated with this improved patient care the
center also experienced earlier recruitment into the cohort.
Due to these contextual differences in sampling for groups 1
and 2, we investigated the comparability of both sample sets.
One identified major difference was the mean time to ART
initiation, which tended to be significantly shorter in the later
period. To compensate for this we compared for 2005–2007
the prevalence of single nucleotide polymorphisms associated
with drug resistance (DR-SNPs) in 75 samples immediately
after ART initiation with 44 samples from delayed ART ini-
tiation. In addition, we considered WHO stage, age, sex,
subtypes, means of CD4 counts, and viral load values. Of all
parameters tested, only the difference in mean age between
both comparison groups was significant (95% confidence in-
terval, 0.5–9.5, p= 0.0396). Since there were no significant
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differences in DR-SNPS or other factors when comparing
samples with early versus late treatment start (Supplementary
Tables S1 and S2; Supplementary Data are available online at
www.liebertpub.com/aid), all 2005–2007 samples were
pooled for comparative analysis with the 2009 data set. Based
on this comparison we concluded that variation in the time to
ART initiation did not introduce a major sampling bias.
Prevalence of HIV-1 subtypes
HIV-1 subtypes were determined from the reverse tran-
scriptase sequence (codon 23 to 236). Subtype frequencies are
shown in Fig. 1 for both study periods. Subtype C was found
to be the most prevalent HIV-1 subtype with a frequency of
43% for the years 2005–2007 and 44% for 2009. Other subtypes
and their frequency of occurrence during our sampling peri-
ods were A1 (32% for 2005–2007 and 27% for 2009), D (18%
and 13%), and recombinants (7% and 15%), respectively
(Table 1). The phylogenetic relationship of the sequences from
2005–2007 and 2009 is shown in Supplementary Figs. S1 and
S2. The corresponding GenBank accession numbers of these
sequences are KC537065–KC537290.
Prevalence of antiretroviral resistance mutations
The major and minor drug resistance mutations in 2005–
2007 and 2009 and their respective frequencies (number of
observed cases in each group of samples) are shown in Tables
3 and 4 and Fig. 2. The frequency of observed mutations was
high overall, but several of these mutations were found to
Table 1. Comparison of Baseline Categorical Characteristics of KIULARCO Patients in 2005–2007 and 2009
Years 2005–2007 Year 2009 Difference in
proportion
Variable Frequency Proportion 95% CI Frequency Proportion 95% CI 95% CI (p)
WHO stage (n= 116) (n = 118)
1 39 0.34 – 0.09 60 0.51 – 0.09 0.05–0.30 ( p= 0.0084)a
2 22 0.19 – 0.07 35 0.3 – 0.08 0.00–0.22 ( p= 0.0678)
3 35 0.30 – 0.08 21 0.17 – 0.07 0.012–0.23 ( p= 0.0319)a
4 20 0.17 – 0.07 3 0.03 – 0.03 0.07–0.22 ( p= 0.0001)a
Sex (n= 117) (n = 118)
Females 80 0.68 – 0.08 74 0.63 – 0.09 - 0.07–0.18 ( p= 0.4108)
DR mutations (n = 120) (n = 119)
Major RTIs 10 0.08 – 0.05 4 0.03 – 0.03 - 0.01–0.11 ( p= 0.1069)
Major NRTIs 4 0.03 – 0.03 1 0.01 – 0.02 - 0.01–0.06 ( p= 0.2128)
Major NNRTIs 9 0.08 – 0.05 4 0.03 – 0.03 - 0.02–0.10 ( p= 0.1666)
Minor RTIs 3 0.03 – 0.03 6 0.05 – 0.04 - 0.02–0.07 ( p= 0.4994)
Minor PIs 16 0.13 – 0.06 7 0.06 – 0.04 0.00–0.15 ( p= 0.0509)
Subtypesb (n= 120) (n = 111)
A1 38 0.31 – 0.09 30 0.27 – 0.08 - 0.07–0.17 ( p= 0.4395)
C 52 0.43 – 0.09 49 0.44 – 0.09 - 0.11–0.14 ( p= 0.9013)
D 22 0.18 – 0.07 15 0.13 – 0.06 - 0.05–0.09 ( p= 0.3183)
A1, C 3 0.03 – 0.02 2 0.02 – 0.02 - 0.07–0.14 ( p= 0.7156)
A1,D 0 0 0 2 0.02 – 0.02 - 0.02–0.07 ( p= 0.1397)
C,D 3 0.03 – 0.02 8 0.07 – 0.05 - 0.02–0.12 ( p= 0.0933)
A1,01_AE 2 0.02 – 0.02 3 0.03 – 0.05 - 0.04–0.07 ( p= 0.5888)
A1,C,D 0 0 — 1 0.01 – 0.02 - 0.03–0.06 ( p= 0.2974)
A1,01_AE,C 0 0 — 1 0.01 – 0.02 - 0.03–0.06 ( p= 0.2974)
All recombinants 8 0.07 – 0.04 17 0.15 – 0.06 - 0.01–0.17 ( p= 0.0345)a
aStatistically significant.
bSubtype assignment according to prediction by Los Alamos database.
CI, confidence interval; DR mutation, drug resistance mutation; NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, nonnucleoside
reverse transcriptase inhibitors; PIs, protease inhibitors.
Table 2. Comparison of Baseline Numeric Characteristics in 2005–2007 and 2009 in KIULARCO Patients
CD4 counts (cells/ml) Viral load (copies/ml) Age (years)
Variable 2005–2007 2009 2005–2007 2009 2005–2007 2009
Median 222 420 50,805 39,920 35 40
95% confidence interval 174–270 359–481 32,070–69,540 9,557–70,283 34–36 38–42
Range 3–1,298 20–2,079 35–1,270,126 1,380–2,417,380 4–85 21–71
Interquantile range (25–75) 236–365 169–310 80,352–146,791 71,770–304,209 8.5–15.5 9.3–16.7
Sample size 117 118 90 63 117 120
Difference between medians 198 10,885 5
95% CI of difference between medians 119–277 23,594–45,364 2.7–7.3
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cluster in few individuals. Thus from these mutation fre-
quencies the prevalence rate of major reverse transcriptase
inhibitor mutations in the baseline samples from individuals
in 2005–2007 was 8.4%, and, quite unexplained, the preva-
lence was lower at 3.3% in 2009. Nucleoside reverse tran-
scriptase inhibitor (NRTI) mutations occurred in 3.4% and
0.8% of all tested individuals in 2005–2007 and 2009, respec-
tively, while the more prevalent nonnucleoside reverse tran-
scriptase inhibitor (NNRTI) mutations were 7.6% and 3.3% for
the same periods. Generally we observed a reduction in DR
mutations (particularly for K103N and Y181C) for HIV-1
subtype C from 2005–2007 to 2009 (Supplementary Table S3).
FIG. 1. Prevalence of HIV-1 subtypes in the Ifakara HIV-1
cohort in 2005–2007 and 2009. Bars represent 95% confidence
intervals. Subtype assignment according to prediction by the
Los Alamos database.
Table 3. Major HIV-1 Drug Resistance Mutations
in Treatment-Naı¨ve Ifakara Patients
in 2005–2007 and 2009
Year
Patient
ID Subtypea Major DR-SNPs Sex
Age
(years)
2005–2007 5410033 D K103N F 42
5510060 D M41L F 40
5510135 C K103N M 47
5510184 A1 M184V, G190A F 29
5510187 C K103N, Y181C F 4
5510259 C K103N F 30
5511494 C K103N F 30
5510599 C Y181C F 51
5510039 A1 M184V, G190A F 31
5510072 C K65KR, K70KR,
L74LV, M184V,
K103N, Y181C
F 45
2009 5514370 A K103N, M184V,
T215F
F 63
5421041 A1 K103N — —
5513670 C K103N M 35
5511139 C K103N M 4
aSubtype prediction according to Stanford HIV-1 Drug Resistance
database, version 6.2.0.
DR-SNPs, drug resistance single nucleotide polymorphisms.
Table 4. Frequency of Observation of HIV-1 Drug
Resistance Single Nucleotide Polymorphisms
in KIULARCO Cohort in 2005–2007 and 2009
2005–2007
(n = 120)
2009
(n = 119)
DR-SNP Frequency (%) Frequency (%)
Major NRTI mutations
M41L 1 (0.8) —
K65KR 1 (0.8) —
K70KR 1 (0.8) —
L74LV 1 (0.8) —
M184V 2 (1.6) 1 (0.8)
M184MV 1 (0.8) —
T215F — 1 (0.8)
Subtotal: major NRTI 7 (5.9) 2 (1.7)
No. of individuals
with major NRT
mutations
4 (3.4) 1 (0.8)
Major NNRTI mutations
K103N 6 (5.0) 4 (3.3)
Y181C 3 (2.5) —
G190A 2 (1.7) —
Subtotal: major NNRTI 11 (9.2) 4 (3.3)
No. of individuals with
major NNRT mutations
9 (7.6) 4 (3.3)
Total major RT
mutations
18 (15.1) 6 (5.0)
No. of individuals with
major RT mutations
10 (8.4) 4 (3.3)
Minor NRTI mutations
M41KM 1 (0.8) —
D67G — 1 (0.8)
D69S 1 (0.8) —
V118I — 3 (2.5)
H221HY 1 (0.8) —
Subtotal: minor NRTI 3 (2.5) 4 (3.3)
Minor NNRTI mutations
V90I — 1 (0.8)
V108I — 1 (0.8)
V179D — 1 (0.8)
G190R 1 (0.8) —
Subtotal: minor NNRTI 1 (0.8) 3 (2.5)
All minor mutations in RT 4 (3.4) 7 (5.8)
Minor protease mutations
L33FL — 1 (0.8)
L10V 9 (7.6) 1 (0.8)
L10I 4 (3.4) 1 (0.8)
L10IL — 1 (0.8)
L10IV 1 (0.8)
V11I 2 (1.7) —
V11IV — 1 (0.8)
L23F 1 (0.8) —
A71T 1 (0.8) —
T74S 1 (0.8) —
L89V — 1 (0.8)
Total: minor protease
mutations
18 (15.1) 7 (5.8)
DR-SNPs, drug resistance single nucleotide polymorphisms; RT,
reverse transcriptase; NRTI, nucleoside reverse transcriptase inhib-
itor; NNRTI, nonnucleoside reverse transcriptase inhibitor.
DRUG-RESISTANT MUTATIONS/HIV-1 SUBTYPES IN TANZANIA 1233
In subtype C viruses the prevalence of K103 was 4.2% for the
period of 2005–2007 while in 2009 it was 1.7%. In addition, the
prevalence of the Y181C mutation was 2.5% for subtype C
viruses in 2005–2007, whereas it was not found at all in our
samples from 2009. No major protease gene mutation was
found in both study periods.
Discussion
The work at the CDCI and subsequently the KIULARCO
cohort in rural Tanzania was initiated at the time of com-
mencing the ART rollout in these two districts. Close clinical
monitoring of patients was installed for guiding treatment
and adaptation of drug regimens. The comprehensive data
continuously gathered for this rapidly growing cohort also
provided the basis for epidemiological studies. A central
question was to what extent the deployment of ART would
drive the development of drug resistance under the specific
conditions of a rural African setting. As in other areas with
limited resources, a number of typical shortfalls can contrib-
ute to treatment failures, e.g., incomplete adherence to treat-
ment, limitations in travel capabilities for patients for their
medical appointments or drug pickup, or stock out of drugs at
health institutions. Despite little prior availability of ART in
the study area some primary resistances, i.e., new infections
with a drug-resistant strain, had to be expected to occur ac-
cording to reports from other areas in Tanzania.12,16 In Tan-
zania the prevention of mother-to-child transmission
(PMTCT) of HIV-1 policy (2009) recommends combination
regimens that include zidovudine (AZT), nevirapine (NVP),
and lamivudine (3TC) in areas with the capacity to offer and
monitor ART. For all other areas with no such capability the
policy recommends only the use of minimum antiretroviral
prophylaxis consisting of a single dose of nevirapine to the
mother and the infant.8 Particularly in the Ifakara area the use
of single dose nevirapine for PMTCT has been practiced since
2004 (Marcel Stoeckle, personal communication). This policy
with less than perfect drug pressure may have contributed to
the development of viral resistance to nevirapine and hence to
the transmission of the drug-resistant HIV-1 strains.17
During the first 3 years of KIULARCO (2005–2007), about
20 cases of suspected resistance had been observed. This as-
sumption was based on clinical parameters or CD4 decline in
the absence of any hint of poor patient’s adherence. The main
driving parameters could have been that in this early phase of
the cohort much of the cost of medication had to be covered by
the patients and distribution was via private pharmacies
(Marcel Stoeckle, personal communication). This prompted
our investigation of the transmission of primary resistance in
the study area. In an attempt to gather baseline data for mo-
lecular epidemiological studies on drug-resistant HIV-1 in-
fections among KIULARCO patients, we compiled two
molecular data sets, one describing the HIV-1 diversity and
subtypes in the study area and the other providing informa-
tion on the prevalence of DR-SNPs in treatment-naive pa-
tients. Because prior to a rollout of ART the transmission of
resistant virus strains is likely a rare event, we expected to find
very few DR-SNPs in treatment-naive individuals.18
HIV-1 subtypes C, A, and D and the recombinant forms
were the most frequent ones identified in KIULARCO par-
ticipants. Despite slight differences in the proportion of these
subtypes, this distribution is overall in line with other reports
from different regions of Tanzania.1 In studies conducted in
the Dar es Salaam, Kilimanjaro, Kagera, and Mbeya regions,
subtypes A and C were also found to be the predominant
HIV-1 subtypes.13,19 Our finding of a higher proportion of
subtype C in Ifakara is plausible, since Ifakara is directly
linked by railway to Zambia, where subtype C prevails.20
Our analysis is representative in the context of other
studies as the pol region has been used previously for sub-
typing HIV-1.1,19 This approach represents a straightforward
way of identifying circulating HIV-1 subtypes in population
studies, especially in resource-poor settings. As evidenced by
the uncertainty about subtype A1 versus CRF01_AE, a limi-
tation of our subtype analysis may, however, lie in the re-
striction to HIV-1 protease and reverse transcriptase as these
sequences might not capture the full diversity and may un-
derestimate/misclassify some of the recombinant forms.13
Overall our findings highlight the diversity of HIV-1 sub-
types in rural Tanzania and contribute further data points to a
countrywide picture of subtype frequencies. The longitudinal
comparison indicates stable subtype frequencies over a period
of at least 4 years with only significant changes in the pro-
portion of recombinants, whereby more recombinants were
observed in 2009 than in 2005–2007 ( p = 0.0345).
We compared the prevalence of DR-SNPs in drug-naive
patients in two surveys, conducted in 2005–2007 and 2009.
The rationale was to describe potential effects of ART rollout
on the prevalence of DR-SNPs. The first sampling period
2005–2007 was chosen closely after the beginning of the
Tanzanian ART program (2004) and the second group of
samples was collected during 2009. We assumed that the ef-
fects of drug pressure might lead to a first visible increase in
transmitted resistance mutations in the population during
subsequent years.
When comparing the two groups of patients, the significant
difference in the prevalence of drug-resistant mutations may
suggest a sampling bias in the sampled patients, e.g., by
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FIG. 2. Prevalence of HIV-1 drug resistance (DR) mutations
in 2005–2007 and 2009 in the Ifakara HIV-1 cohort. RTIs,
reverse transcriptase inhibitors; NRTIs, nucleoside reverse
transcriptase inhibitors; NNRTIs, nonnucleoside reverse
transcriptase inhibitors; PIs, protease inhibitors. Bars repre-
sent 95% confidence.
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sampling in distinct populations with different levels of drug
exposure/experience. Of note, the first analysis period 2005–
2007 falls into the early rollout period. During this time no drug
distribution or only standardization in drug distribution was
established (mostly through private pharmacies), and many of
the patients had to pay for the drugs. These two factors cer-
tainly introduced great uncertainty and possibly suboptimal
drug dosing as it largely depended on the patients’ financial
situation. For the latter time period (2009) government-driven
drug distribution programs made the medication freely avail-
able for the patients rendering the likelihood of continuous
drug availability for the patient higher.
Between our study periods also the context of patient re-
cruitment might have differed. We studied treatment-naive
patients from two time periods: 2005–2007, representing the
initial years of the KIULARCO cohort and of drug rollout, and
about 4 years after this period. As expected, we found some
differences in baseline characteristics between our two
groups, e.g., in median CD4 counts and viral loads. Differ-
ences in the time to initiation of ART could explain the ob-
served discrepancy. To probe whether these differences were
relevant for our research question, we analyzed in parallel
samples from patients with immediate ART initiation versus
later initiation and found that both subgroups of 2005–2007
samples were very comparable without significant differences
with respect to the prevalence of DR-SNPs. This prompted us
to analyze in 2009 samples from treatment-naive individuals
irrespective of the time point at which these study participants
started ART. Therefore we cannot rule out that a discrepancy
in the time to ART initiation has contributed to the observed
differences (samples of 2005–2007 had slightly lower median
CD4 counts and higher median viral loads than the 2009
group), despite our result indicating comparability between
the two subsets from 2005–2007.
When comparing the prevalence of major reverse tran-
scriptase mutations for 2005–2007 versus 2009 we found a
higher prevalence (8.4%) in samples from earlier years than in
2009 (3.3%). This difference in prevalence was not statistically
significant ( p= 0.1069). The prevalence of nonnucleoside re-
verse transcriptase mutations was 3.4% in 2005–2007 and
0.8% in 2009, respectively ( p= 0.2128). The higher rate of
mutations in earlier years might reflect the specific context of
sampling right at the beginning of ART rollout in the region.
Of note, more patients in 2005–2007 than in 2009 were judged
as WHO clinical stages 3 and 4. Thus more patients at WHO
clinical stages 3 and 4 were enrolled in the KIULARCO cohort
at the start of the Tanzanian ART program. And we might
expect a higher prevalence of DR-SNPs after the extended
treatment period of 5 years of ART in the Ifakara cohort.
However, we observed that over time the number of DR-
SNPs had rather decreased (2009 vs. 2005–2007). We believe
that the initial therapy situation provides a most plausible
explanation. Before 2007 the drug distribution system was not
yet well established, and many patients had to pay for their
drugs. In low-income areas of our study this will have inev-
itably led to situations of suboptimal drug availability and
irregular drug dosing and is likely seen in our figures, which
reflect the improving national HIV treatment management
system in Tanzania.
The NNRTI mutations K103N, Y181C, and G190A cause
high-level resistance to nevirapine, one of the most common
NNRTI drugs used in Ifakara and elsewhere in Tanzania.21,22
All individuals with DR-SNPs in 2009 and 60% of individuals
in 2005–2007 carried the K103N mutation. The high preva-
lence of the K103N mutation correlates with the use of ne-
virapine monotherapy for PMTCT in Tanzania.8 And the
preexistence of this mutation likely influences the outcome of
ART by allowing an early start for the further accumulation of
DR-SNPs under suboptimal drug pressure. KIULARCO and
other Tanzanian ART programs can offer only few treatment
options.21 The observed level of primary resistance must
therefore be considered a potential threat to the effectiveness
of the current Tanzanian ART program.17,22
In summary, our study identified DR-SNPs in drug-naive
patients during both periods, immediately after ART intro-
duction in Tanzania and 4–5 years after. We identified a trend
toward lower mutation frequencies in samples collected later
in the cohort. Minor differences in the repertoire of mutations
might reflect individual introductions from abroad, a finding
due to the small sample size. The overall number of patients in
the KIULARCO study under ART was 1,491 in December
2008.14 These numbers might still be too small to describe any
stable trends in transmitted resistance mutations within 4
years, but the observed findings will be followed-up in the
coming years.
Overall our findings are in agreement with genotypic re-
sults from other African studies and confirm that primary
drug resistance mutations are present in treatment-naive pa-
tients even before the scale up of ART.12,16
Conclusions
Our molecular typing provides the baseline information on
HIV-1 strains identified in a rural area in southern Tanzania.
Our data support a stable subtype distribution and an overall
low prevalence of preexisting drug resistance. Monitoring the
extent and significance of HIV-1 drug resistance mutations in
treatment-naive individuals is and will continue to be a key
for an informed choice of optimal ART and thus can con-
tribute to efforts toward preventing the spread of HIV-1 drug
resistance.
Sequence Data
The GenBank accession numbers for the RT sequences
generated in this work are KC537065–KC537290.
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